Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, a biotech startup leveraging AI to discover drugs from the natural world, raised a $311 million Series E at a $2 billion valuation, doubling its valuation from 12 months prior. The round was led by Catalio Capital Management with participation from Iconiq and others. Founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals, Enveda aims to harness powerful medicines from plants and microbes rather than synthesizing them from scratch. While no FDA-approved AI-discovered drugs exist yet, Enveda is among companies advancing AI-discovered candidates into human clinical trials, currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.

(Source：TechCrunch)